Evogene Stock Performance
| EVGN Stock | USD 1.41 0.03 2.08% |
On a scale of 0 to 100, Evogene holds a performance score of 5. The firm shows a Beta (market volatility) of 1.25, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Evogene will likely underperform. Please check Evogene's semi variance, and the relationship between the treynor ratio and rate of daily change , to make a quick decision on whether Evogene's price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Evogene are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain technical and fundamental indicators, Evogene displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:10 | Last Split Date 2024-07-25 |
1 | Evogene Coverage Initiated at StockNews.com | 01/23/2025 |
2 | Agricultural Biologicals Market to Grow by USD 14.76 Billion from 2025-2029, Driven by Rising Chemical Fertilizer Prices, Report on AI Driving Market Transforma... | 02/12/2025 |
3 | Evogene Sets Date for Q4 Earnings Key Details for Your Calendar - StockTitan | 02/20/2025 |
4 | Evogene Q4 Earnings Snapshot | 03/06/2025 |
5 | Evogene Ltd Q4 2024 Earnings Call Highlights Revenue Growth and Strategic ... | 03/07/2025 |
6 | Evogene Ltd. Q4 2024 Earnings Call Transcript | 03/10/2025 |
| Begin Period Cash Flow | 29 M |
Evogene |
Evogene Relative Risk vs. Return Landscape
If you would invest 124.00 in Evogene on December 18, 2024 and sell it today you would earn a total of 17.00 from holding Evogene or generate 13.71% return on investment over 90 days. Evogene is currently generating 0.3318% in daily expected returns and assumes 4.9789% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Evogene, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evogene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evogene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Evogene, and traders can use it to determine the average amount a Evogene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0666
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EVGN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.98 actual daily | 44 56% of assets are more volatile |
Expected Return
| 0.33 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Evogene is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evogene by adding it to a well-diversified portfolio.
Evogene Fundamentals Growth
Evogene Stock prices reflect investors' perceptions of the future prospects and financial health of Evogene, and Evogene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evogene Stock performance.
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.94) % | ||||
| Operating Margin | (2.83) % | ||||
| Current Valuation | 6.96 M | ||||
| Shares Outstanding | 6.8 M | ||||
| Price To Earning | (5.22) X | ||||
| Price To Book | 4.71 X | ||||
| Price To Sales | 1.14 X | ||||
| Revenue | 5.64 M | ||||
| Gross Profit | 5.83 M | ||||
| EBITDA | (23.2 M) | ||||
| Net Income | (25.95 M) | ||||
| Cash And Equivalents | 35.25 M | ||||
| Cash Per Share | 0.86 X | ||||
| Total Debt | 11.51 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 6.80 X | ||||
| Book Value Per Share | (0.21) X | ||||
| Cash Flow From Operations | (21.58 M) | ||||
| Earnings Per Share | (2.89) X | ||||
| Market Capitalization | 9.72 M | ||||
| Total Asset | 51.1 M | ||||
| Retained Earnings | (257.59 M) | ||||
| Working Capital | 27.52 M | ||||
| Current Asset | 104.38 M | ||||
| Current Liabilities | 5.64 M | ||||
About Evogene Performance
By examining Evogene's fundamental ratios, stakeholders can obtain critical insights into Evogene's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Evogene is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 14.76 | 15.49 | |
| Return On Tangible Assets | (0.72) | (0.69) | |
| Return On Capital Employed | (0.69) | (0.66) | |
| Return On Assets | (0.54) | (0.56) | |
| Return On Equity | (2.28) | (2.16) |
Things to note about Evogene performance evaluation
Checking the ongoing alerts about Evogene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evogene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evogene may become a speculative penny stock | |
| Evogene had very high historical volatility over the last 90 days | |
| Evogene has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 5.64 M. Net Loss for the year was (25.95 M) with profit before overhead, payroll, taxes, and interest of 5.83 M. | |
| Evogene currently holds about 35.25 M in cash with (21.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86. | |
| Evogene has a poor financial position based on the latest SEC disclosures | |
| Latest headline from insidermonkey.com: Evogene Ltd. Q4 2024 Earnings Call Transcript |
- Analyzing Evogene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evogene's stock is overvalued or undervalued compared to its peers.
- Examining Evogene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evogene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evogene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evogene's stock. These opinions can provide insight into Evogene's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.89) | Revenue Per Share | Quarterly Revenue Growth 1.787 | Return On Assets | Return On Equity |
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.